| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-30 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
| filingDate |
2006-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2008-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008540454-A |
| titleOfInvention |
Diallyl-purine, -azapurine and -deazapurine as non-nucleoside reverse transcriptase inhibitors for the treatment of HIV |
| abstract |
The present invention relates to 2-phenylamino-6-arylamino-, 6-aryloxy-, and 6-arylthio-purines, -azapurines, and -deazapurines. The compounds of the present invention are non-nucleoside reverse transcriptase inhibitors and have the potential as anti-HIV treatments. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10562902-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016526550-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018525394-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020203929-A |
| priorityDate |
2005-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |